174 related articles for article (PubMed ID: 15679425)
1. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes.
Dunphy CH
Arch Pathol Lab Med; 2005 Feb; 129(2):219-22. PubMed ID: 15679425
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease.
Stevens EC; Rosenthal NS
Am J Clin Pathol; 2001 Aug; 116(2):177-82. PubMed ID: 11488063
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
Michiels JJ; Thiele J
Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
[TBL] [Abstract][Full Text] [Related]
4. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis.
Lawrence JB; Friedman BS; Travis WD; Chinchilli VM; Metcalfe DD; Gralnick HR
Am J Med; 1991 Dec; 91(6):612-24. PubMed ID: 1750431
[TBL] [Abstract][Full Text] [Related]
5. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
[TBL] [Abstract][Full Text] [Related]
6. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
9. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
10. Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Mesa RA
Biologics; 2007 Jun; 1(2):129-38. PubMed ID: 19707323
[TBL] [Abstract][Full Text] [Related]
11. Using 4-color flow cytometry to identify abnormal myeloid populations.
Kussick SJ; Wood BL
Arch Pathol Lab Med; 2003 Sep; 127(9):1140-7. PubMed ID: 12946231
[TBL] [Abstract][Full Text] [Related]
12. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
Bartl R; Frisch B; Wilmanns W
Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
[TBL] [Abstract][Full Text] [Related]
13. [Chronic myeloproliferative disorders. The new WHO classification].
Thiele J; Kvasnicka HM
Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
[TBL] [Abstract][Full Text] [Related]
14. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
15. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
16. Hematologic aspects of systemic mastocytosis.
Parker RI
Hematol Oncol Clin North Am; 2000 Jun; 14(3):557-68. PubMed ID: 10909040
[TBL] [Abstract][Full Text] [Related]
17. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Steensma DP; Dewald GW; Lasho TL; Powell HL; McClure RF; Levine RL; Gilliland DG; Tefferi A
Blood; 2005 Aug; 106(4):1207-9. PubMed ID: 15860661
[TBL] [Abstract][Full Text] [Related]
18. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.
Thiele J; Kvasnicka HM
Leuk Lymphoma; 2006 Mar; 47(3):381-96. PubMed ID: 16396760
[TBL] [Abstract][Full Text] [Related]
19. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
[TBL] [Abstract][Full Text] [Related]
20. The histopathology of chronic myeloproliferative diseases.
Georgii A; Buesche G; Kreft A
Baillieres Clin Haematol; 1998 Dec; 11(4):721-49. PubMed ID: 10640214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
